Sponsors and Exhibitors Company Profiles

AbbVie​

1 North Waukegan Road

North Chicago, IL 60064-6075

www.abbvie.com

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories.  The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.  AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries.  For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com.  Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

 

AstraZeneca

2 Kingdom St
London W2 6BD
United Kingdom

http://www.astrazeneca.com

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

 

Baxter AG
Industriestrasse 67
A-1221 Vienna
Austria
www.baxter.com

Baxter International Inc. through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

 

ESPID European Prudent Paediatric Antibiotic Prescribing Online Course

ESPID 2014 Congress, May 7-9, 2014

Dublin, Ireland

www.penta-id.org

The ESPID European Prudent Paediatric Antibiotic Prescribing Online Course aims to provide internet-based training to help participants develop specific competencies relevant to antibiotic prescribing and to the management of antimicrobial resistance in the inpatient neonatal and paediatric setting, including:

  • Antibiotic modes of action and uses
  • Antibiotics resistance mechanisms
  • Prescribing antibiotics for infections caused by susceptible and resistant organisms
  • Antimicrobial stewardship
  • Monitoring and surveillance

The course will focus on inpatient use of antibiotics and will target physicians in general or those undertaking specialist paediatric training. It may also be useful for paediatric infectious diseases trainees and physicians involved in antimicrobial stewardship.

 

European Society for Immunodeficiencies (ESID)

1-3 rue Chantepoulet

1211 Geneva

Switzerland

http://esid.org/

ESID was created in 1994 and has been striving to improve the knowledge in the field of PID by encouraging research, developing educational programmes and fostering cooperation among all those involved in the diagnosis, treatment and management of these diseases.

ESID believes that every child, adolescent and adult born with a defective immune system has the right to benefit from both clinical and scientific knowledge.
Therefore, our mission is to enable patients with primary immunodeficiency diseases to live their lives to its full potential by improving awareness, diagnosis, treatment, education and understanding of these diseases.
As the leading society in the field, ESID is committed to promote collaboration between healthcare professionals, patient organisations, industry and governmental bodies and to foster education and research.

 

The ESPID-Oxford Course - Hot Topics in Infection and Immunity in Children

University of Oxford, Department of Paediatrics

Children's Hospital, Headington

Oxford OX3 9DU

United Kingdom

www.oxfordiic.org

Hot Topics in Infection and Immunity in Children, The ESPID-Oxford Course, aims to provide both basic information and updates in key areas of paediatric infectious disease.  It is held in Oxford, UK each summer, with 30 leading experts from around the world, providing updates on the latest developments in the field.  It is also a residential component of the ESPID-Oxford Postgraduate Diploma in PID.

 

GlaxoSmithKline

89 rue de l'Institut

Rixensart 1330

Belgium

www.gsk.com

GSK is the world's leading vaccine company. We are active in vaccine research, development and production with over 30 vaccines approved and at least 15 more in development. Our portfolio includes vaccines to prevent potentially life-threatening or crippling illnesses such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza and bacterial meningitis. Headquartered in Belgium, we operate 13 manufacturing sites strategically positioned around the world. In 2012, we distributed nearly 900 million doses of vaccine to 170 countries in both the developed and the developing world. For further information, please visit www.gsk.com.

 

Novartis Vaccines & Diagnostics, Inc.

350 Massachusetts Avenue
Cambridge, MA 02139
USA

www.novartisvaccines.com

Novartis Vaccines is a global leader in vaccine research, development and manufacturing. Novartis is committed to protecting against meningococcal disease, which can manifest as meningitis and sepsis, and manufactures vaccines against the five common disease-causing serogroups – A, B, C, W-135, Y1,2. Novartis developed Bexsero® [Meningococcal group B Vaccine (rDNA, component, adsorbed)], the only licensed broad-coverage vaccine to help protect against meningococcal disease caused by serogroup Ba,b,3,4. Influenza vaccines are also a core franchise and we recently launched Flucelvax® (Influenza Virus Vaccine), developed using cell-culture technology5,6,7. Our portfolio includes 15 marketed products and 18 vaccine candidates or new indications in development8.

​Footnotes
aBexsero is not expected to provide protection against all circulating meningococcal group B strains.
bBexsero is not currently licensed in the United States.


Pfizer International Operations

23-25 ave du Dr Lannelongue

Paris 75668

France

www.pfizer.eu

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer products.  Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

 

Sanofi Pasteur MSD

160-162 avenue Jean Jaures

CS 50712

69367 Lyon cedex 07

www.spmsd.com

Sanofi Pasteur MSD is a European joint venture formed between Sanofi Pasteur (the vaccine division of Sanofi) and Merck (known as MSD outside the United States and Canada). Combining innovation and expertise, Sanofi Pasteur MSD is the only European pharmaceutical company dedicated exclusively to the development of vaccines. Sanofi Pasteur MSD makes use of the combined expertise resulting from Sanofi Pasteur and Merck's research to focus on the development of new vaccines in Europe in order to produce the most effective, most acceptable and better tolerated vaccines.

 

Statens Serum Institut

Artillerivej 5

2300 Copenhagen S

Denmark

www.ssi.dk/english.aspx

SSI is a public enterprise under the Danish Ministry of Health. For more than 100 years SSI's main task has been to secure the preparedness towards infectious diseases and congenital disorders. The tasks have been expanded, and today, SSI is an international research, production and service enterprise.

SSI's tasks include:

  • Collection and communication of data concerning the health status of the Danish population including financial and quality control data of the Danish healthcare system.
  • Ensuring national frameworks and standards for e-Health in the Danish healthcare system and managing and developing IT systems for the Danish Ministry of Health.
  • Surveillance and control of infectious diseases and congenital disorders.
  • Reference laboratories for infectious, autoimmune, congenital and genetic diseases.
  • Ensuring the supply of vaccines, other biological products and diagnostic services through production and procurement.
  • Preparedness against biological terrorism.
  • Research and development in the Institute's areas of activity at an international level.

SSI aims to ensure advanced control of infectious diseases, including new infections and biological threats.

 

Wisepress Medical Bookshop

25 High Path

Merton Abbey

London

SW19 2JL

UK

bookshop@wisepress.com

www.wisepress.com

Wisepress are Europe's principal conference bookseller. We exhibit the leading books, sample journals and digital content relevant to this meeting. Books may be purchased at the booth, and we offer a postal service. Visit our online bookshop for special offers and follow us on Twitter for the latest news @WisepressBooks.    ​

Keep Me Updated

key dates

Key Dates